The FDA has approved the CardioMEMSHF System, the first implantable, wireless device with remote monitoring to measure
pulmonary artery pressure and heart rate in certain patients with heart failure. The device is approved to be used in patients with New York Heart Association (NYHA) Class III heart failure who have “been hospitalised for heart failure in the previous year,” according to the FDA.
The device allows monitoring the condition of heart patients remotely, as the device is used by patients outside of hospital. The device—which provides information on systolic, diastolic, and mean pulmonary artery pressures—sends data to clinicians who can then make decisions for the patient and, if necessary, make changes in medical therapy.